The role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome X has recently been recognized. Allopurinol has previously been shown to improve endothelial dysfunction, reduce oxidative stress burden, and improve myocardial efficiency. In this "proof of concept" study, we investigated the effect of allopurinol on exercise capacity, coronary and peripheral endothelial function, and serum B-type natriuretic peptide (BNP: a marker of cardiac function and myocardial ischemia) in patients with cardiac syndrome X.
| INTRODUCTION
Patients with cardiac syndrome X (typical anginal-like chest pain and normal coronary arteriograms) represent a heterogeneous syndrome, which encompasses different pathogenic mechanisms.
1 Many patients have angina pectoris that may be due to transient myocardial ischemia. 2 Microvascular abnormalities, caused by coronary endothelial dysfunction, may be responsible for myocardial ischemia in patients with cardiac syndrome X. 3 Oxidative stress with increased production of reactive oxygen species may be one of the main mechanisms contributing to this microvascular endothelial dysfunction. 4 Basal superoxide production has been shown to predict future cardiovascular events in this patient group 5 that might suggest an important pathophysiological role of oxidative stress. It has been proposed that the improvement in endothelial function observed with combined treatment with a statin and angiotensin-converting enzyme (ACE)
inhibitor in patients with cardiac syndrome X may be related to a reduction in oxidative stress. 6 However, to the best of knowledge, there have been no studies that have studied the direct effects of reducing oxidative stress in patients with cardiac syndrome X.
We have previously shown that high-dose allopurinol (600 mg/day) improved endothelial function, as assessed by forearm venous occlusion plethysmograph in patients with chronic heart failure by its ability to reduce oxidative stress, independently of any effect on urate levels. 7 Additionally, this high-dose allopurinol markedly reduced vascular oxidative stress, as assessed by vitamin C and acetylcholine co-infusion studies. These observations would suggest that allopurinol could be used to reduce oxidative stress in cardiac syndrome X.
In this study, we hypothesized that allopurinol offers dual benefits of improving vascular function and reducing myocardial ischemia in patients with cardiac syndrome X. Thus, the objective of this study was to investigate the effects of allopurinol on coronary and peripheral endothelial function, serum B-type natriuretic peptides (BNP-a marker of cardiac function and myocardial ischemia), and maximum exercise time on treadmill testing in patients with cardiac syndrome X.
| METHODS

| Study design
This was a double-blind, crossover trial comparing the effects of allopurinol and placebo on exercise capacity, coronary and peripheral endothelial function, and serum BNP levels in patients with this syndrome. Patients with cardiac syndrome X were randomized to a 6-week treatment with either allopurinol (600 mg/day) or placebo.
After 4 weeks of washout period, they were crossed over to the other arm.
| Study patients
After approval by the Scottish Research Ethics Committee (REC Ref:
07/S1401/103), eligible patients provided written informed consent to participate. We recruited patients with cardiac syndrome X that had smooth unobstructed epicardial arteries shown on coronary angiography at Ninewells Hospital, Dundee.
| Presence of symptoms and evidence of ischemia
All had ongoing typical anginal-type chest pain and at least one objective evidence of myocardial ischemia: documented ≥1 mm of flat ST-segment depression on treadmill exercise testing and/or myocardial reversible perfusion abnormalities during adenosine stress as assessed by technetium-99 m myocardial perfusion imaging.
All patients underwent pretrial screening with blood tests and echocardiography. All had normal left and right ventricular structure and function with no evidence of significant valvular heart disease.
All patients had given their written informed consent to participate in the study.
| Study protocol
Following consent, participants continued on their usual antianginal medications that remained unchanged during the study period. A flowchart of this study is shown in Figure 1 . To allow participants to be familiarized with exercise testing, all underwent treadmill test 1-2 weeks prior starting study medication.
Thereafter, they underwent a baseline exercise stress test and venesection for general hematological and biochemical analyses prior starting study medication (allopurinol or placebo). Patients were randomly assigned to treatment with either allopurinol or placebo 300 mg once daily for the first week, and then uptitrated to a maintenance dose of 300 mg twice a day for further 5 weeks (total treatment period = 6 weeks). At the end of this first treatment period, patients underwent a 4-week washout period after which they crossed over to the alternate treatment arm for another 6 weeks. Coronary vascular function, peripheral endothelial function, exercise testing, and serum BNP level were carried out at baseline and repeated at the end of each treatment period by investigators who were blinded to the treatment regimen. All studies were performed in the morning following an overnight fast, and patients were not allowed to have caffeinated drinks or smoke for 12 hours before the tests.
| Measurements of interest
| Exercise treadmill test
The treadmill exercise test (an objective measure of myocardial is- cardiac cycles at end-expiration. The endothelium-independent vasodilator capacity of the coronary microcirculation was assessed using spectral Doppler imaging during hyperemic condition following 2 minutes of intravenous adenosine (140 μg/kg/min) infusion. Mean diastolic velocities were measured at baseline and at peak hyperemic condition from the Doppler signal recordings. These measurements were averaged over three cardiac cycles. For adenosine infusion, coronary flow reserve (CFR) was defined as the ratio of hyperemic to basal mean diastolic velocities. The interobserver variability and intra-observer variability for the measurement of coronary Doppler velocity recordings in our laboratory were 4.9% and 4.0%, respectively. All patients had continuous heart rate and ECG monitoring. Blood pressure was recorded at baseline and during adenosine infusion, and at recovery.
| Assessment of coronary flow reserve
| Assessment of peripheral endothelial function
Flow-mediated dilatation of brachial artery Endothelium-independent vasodilatation was assessed with duplex ultrasound in the upper extremity before and 5 minutes after administration of 0.4 mg of sublingual nitroglycerin. We have an excellent intrapatient coefficient variation of only 2% in our vascular laboratory.
| Statistical methods
Results from continuous data are shown as mean ± 1 standard deviation. Absolute difference expressed as percentage between allopurinol and placebo.
| RESULTS
The clinical characteristics, past medical history, and medications are shown in Most participants were on anti-anginal therapy, which includes betablockers, nitrate, or calcium channel blockers. All patients completed the study.
Allopurinol treatment resulted in a significant reduction in serum uric acid levels when compared to placebo (−48 ± 24% vs 1.9 ± 11%, P < .001). However, there was no significant difference in maximum exercise time, CFR, and FMD between allopurinol and placebo treatment arms ( Table 2 ). There was a trend that allopurinol reduced serum BNP levels when compared to placebo [−8%
(interquartile range −22%-65%) vs 44% (interquartile range −18%-140%); P = .07).
Noteworthy, there were no adverse effects of treatment reported.
| DISCUSSION
Morbidity of patients with cardiac syndrome X is high, and it is associated with continuing episodes of chest pain, hospital readmission.
Importantly, a history of persistent chest pain in these patients has been shown to predict cardiovascular events. 9 Management of this syndrome represents a major challenge to the treating physician, and understanding the mechanism underlying the condition is of vital importance for patient management. Conventional therapies with antianginal agents such as nitrates, calcium channel antagonists, classic β-adrenoceptor blockers, and nicorandil have been tried with variable success. 10 However, this variable success might be related to a failure to target the underlying pathophysiology.
Allopurinol is not only a drug that has been used for the treatment of gout; it has also been previously shown to reduce oxidative stress, which is one of the important pathogenesis of cardiac syndrome X.
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However, in this current study, we showed that high-dose allopurinol did not have any significant impact in exercise capacity on treadmill testing. Allopurinol also had no effect on endothelial function when assessed using echocardiographic Doppler-derived CRF as well as by FMD of the brachial artery. These findings contrast with our previous study that showed that a similar high dose of allopurinol was able to improve exercise time in patients with chronic stable angina. 11 We did, however, observe a modest trend of a reduction in serum BNP with allopurinol. There is some evidence to suggest that BNP may be related to myocardial ischemia. Goetze et al 12, 13 had previously demonstrated an increase in BNP expression and rapid release of newly synthesized proBNP as a result of myocardial ischemia. BNP levels have also been shown to be related to myocardial ischemia in patients with cardiomyopathy. 14 Clearly, further studies are needed to further investigate this observation.
| LIMITATIONS
This study is relatively small and is likely to be not adequately powered to definitively assess the efficacy of allopurinol in patients with cardiac syndrome X. As this was a crossover study, there are potential "carryover" effects between treatments that might have confounded the estimates of the treatment effects. However, we used a 4-week washout period that has been shown to be sufficient in our previous published crossover study using high-dose allopurinol.
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| CONCLUSION
In patients with cardiac syndrome X, we showed that high-dose allopurinol did not improve exercise capacity, and coronary or peripheral endothelial function.
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